HKEX Filings
-
Sep 16, 2022
2022 Interim Report
-
Sep 15, 2022VOLUNTARY ANNOUNCEMENT - AMENDMENT TO THE ADVANCE PURCHASE AGREEMENT
-
Sep 6, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES SUPERIOR BOOSTER RESPONSES COMPARED TO INACTIVATED VACCINE
-
Sep 2, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended August 31, 2022
-
Aug 30, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 BOOSTER VACCINE CANDIDATE DEMONSTRATES ROBUST NEUTRALIZATION OF DOMINANT OMICRON BA.5 SUBVARIANT
-
Aug 25, 2022VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE 2/3 RESULTS IN ADOLESCENTS FOR CLOVER'S COVID-19 VACCINE
-
Aug 24, 2022INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022
-
Aug 11, 2022DATE OF BOARD MEETING
-
Aug 4, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended July 31, 2022
-
Jul 19, 2022GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
-
Jul 4, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended June 30, 2022
-
Jun 27, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES STRONG CROSS-NEUTRALIZATION AGAINST OMICRON AS A HOMOLOGOUS BOOSTER
-
Jun 20, 2022LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
-
Jun 20, 2022APPOINTMENT OF NON-EXECUTIVE DIRECTORS
-
Jun 14, 2022VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PATIENT WITH SCB-219M IN PHASE 1 TRIAL FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
-
Jun 14, 2022VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PARTICIPANTS IN PHASE 3 TRIAL EVALUATING SCB-2019 AS A HETEROLOGOUS COVID-19 BOOSTER FOLLOWING PRIOR VACCINATION WITH INACTIVATED, MRNA OR VIRAL VECTOR VACCINES
-
Jun 7, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended May 31, 2022
-
Jun 5, 2022INSIDE INFORMATION - BUSINESS UPDATE
-
May 31, 2022VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PARTICIPANTS IN PHASE I TRIAL WITH SCB-2020S, A POTENTIALLY BROADLY PROTECTIVE CHIMERIC COVID-19 VACCINE CANDIDATE
-
May 27, 2022Fourth Amended and Restated Memorandum and Articles of Association
